Safety and Efficacy of an Intrastromal Transform™ Corneal Allograft (TCA) for Presbyopia Correction

• ClinicalTrials.gov Identifier: NCT03671135
• Recruitment Status: Unknown
• First Posted: September 14, 2018
• Last Update Posted: March 10, 2020
• Sponsor: Allotex, Inc.
• Information provided by (Responsible Party): Allotex, Inc.

Study Description

Brief Summary:

The objective of this clinical study is to evaluate the safety and effectiveness of intrastromal implantation of the Allotex TransForm corneal allograft (TCA) for improving near vision in presbyopic subjects.

Condition or disease	Intervention/treatment	Phase
Presbyopia	Other: TCA Intrastromal Inlay	Not Applicable

Detailed Description:

Beginning in 1949 with the pioneering work of Jose Barraquer, there has been an interest in using natural corneal tissue to change the refractive properties of the eye. In recent years, non-allogenic, synthetic corneal implants have received marketing approval in the United Stated and Europe for refractive purposes. Although synthetic implants are made of biocompatible materials they are not equivalent to an allogenic implant in terms of biocompatibility. The Allotex TCA is a piece of acellular cornea, sterilized with electron beam radiation and shaped to a particular shape using a laser. The availability of precise laser shaping systems and sterile corneas are the key factors that make the use of allogenic implants possible.

The TCA is placed in an intrastromal flap (Just beneath Bowmans layer) created using a femtosecond laser. The goal is to enhance the visual performance of the patient with a material that is 100% biocompatible and precisely shaped for the individual's needs.

Subjects must be presbyopic adults, needing from +1.75 D to +3.50 D of reading add in the non-dominant eye and must have uncorrected near visual acuity worse than 20/40 in the non-dominant eye. Bilateral treatments will not be allowed during this study.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 121 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: Single group assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Prospective Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Intrastromal Implant of the Transform Corneal Allograft (TCA) for Providing Near Vision in Presbyopic Subjects
• Actual Study Start Date: August 9, 2018
• Estimated Primary Completion Date: September 2021
• Estimated Study Completion Date: September 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: TCA Intrastromal Inlay; A monocular intrastromal corneal inlay will be implanted.	Other: TCA Intrastromal Inlay; Anterior surface of Bowmans Layer Corneal Optical Correction Inlay

Outcome Measures

Primary Outcome Measures :

1. Assessment of the accuracy and stability of Presbyopic refractive correction following intervention with the Transform™ Corneal Allograft Inlay. [ Time Frame: 6 months ]
   The primary effectiveness endpoint is an improvement in uncorrected near visual acuity (at 40 cm) at 6 months post-operativelyto20/40 or better. The goal is that more than 65% of eyes should have an uncorrected near visual acuity (UCNVA) of 20/40 or better at 6 months postoperatively.

Eligibility Criteria

• Ages Eligible for Study: Child, Adult, Older Adult
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Provide informed consent, have signed the written informed consent form, and been given a copy.
• Presbyopic adults, needing from +1.75 D to +3.50 D of reading add in the nondominant eye to improve near visual acuity at 40 cm by at least one line or more.
• Uncorrected near visual acuity worse than 20/40 in the non-dominant eye.
• Distance visual acuity correctable to at least 20/20 in both eyes.
• Near visual acuity correctable to at least 20/20 in both eyes.
• Manifest refraction spherical equivalent (MRSE) between -0.75 and +1.00 D with ≤0.75 D of refractive cylinder in the non-dominant eye.
• Stable vision, i.e. MSRE within 0.50 D over prior 12 months in the non-dominant eye.
• Contact lens wearers must discontinue hard or rigid gas permeable lenses for at least 2 weeks and discontinue soft lenses for at least 3 days prior to baseline examination.
• Contact lens wearers must have two (2) central keratometry readings with regular mires and two (2) manifest refractions taken at least one week apart, with no contact lens wear between. Keratometric values must not differ by more than ±0.50 D in any meridian and MRSE values must not differ more than ±0.50 D in the non-dominant eye.
• Average corneal power of ≥ 35.00 D and ≤ 47.00 D in the non-dominant eye.
• Subjects must be willing and able to return for scheduled follow-up examinations for 24 months after surgery.

Exclusion Criteria:

• A difference of > 0.75 D between the manifest refraction spherical equivalent and the cycloplegic refraction spherical equivalent in the non-dominant eye.
• Anterior segment pathology in the non-dominant eye.
• Signs or symptoms of clinically significant cataracts in the non-dominant eye.
• Residual, recurrent, active ocular or uncontrolled eyelid disease, or any corneal abnormality (including endothelial dystrophy, recurrent corneal erosion, etc.) in the non-dominant eye.
• Topographic signs of keratoconus (or keratoconus suspect) or other ectatic disorders in either eye.
• Subjects with clinically significant dry eyes, as determined by Tear Breakup Time (TBUT) of < 7 seconds or the presence of greater than mild symptoms of dryness or discomfort or SPK greater than grade 1.
• Distorted or unclear corneal mires on topography maps of the non-dominant eye.
• Macular degeneration, retinal detachment, or any other fundus pathology that would prevent an acceptable visual outcome in the non-dominant eye.
• Central corneal thickness <470 microns in either eye.
• Any prior intraocular surgery except corneal refractive surgery is allowed if performed more than 6 months prior to study participation.
• History of herpes zoster or herpes simplex keratitis in the non-dominant eye.
• History of steroid-responsive rise in intraocular pressure (IOP), preoperative IOP >21 mm Hg, glaucoma, or are a glaucoma suspect in the non-dominant eye.
• Using systemic medications with significant ocular side effects.
• Pregnant, lactating, or planning to become pregnant during the course of the study.
• Known sensitivity to planned study concomitant medications.
• Participating in any ophthalmic drug or device clinical trial during the time of this clinical investigation.

Contacts and Locations

Locations

Austria

Gemini Augenlaser Wien

Vienna, Opernring 1, Austria, 1010

Sekhraft Augenzentrum Wien

Vienna, Austria, 1010

Belgium

Medipolis Wilrijk

Antwerp, Boomsesteenweg 223, Belgium, B-2610

France

Hospital Pierre Paul Riquet

Toulouse, Purpan, France, 31300

Institute Laser Vision Noemie de Rothschild, Fondation Ophthalmolique Adolphe de Rothschild

Paris, France, 75019

Ireland

Wellington Eye Clinic

Dublin, Beacon Court Sandyford, Ireland, 18

Switzerland

Laser Vista

Basel, Switzerland, 4051

Eye Clinic Orasis AG

Reinach AG, Switzerland, 5734

United Kingdom

Corneo Plastic Unit and Eye Bank Queen Victoria Hospital

East Grinstead, United Kingdom, RH19 3DZ

Centre for Sight

London, United Kingdom, W1G 8HZ

Optegra Eye Hospital

London, United Kingdom

Sponsors and Collaborators

Allotex, Inc.

Investigators

• Study Director: Vance Thompson, MD; Study Medical Monitor/Consultant

More Information

• Responsible Party: Allotex, Inc.
• ClinicalTrials.gov Identifier: NCT03671135
• Other Study ID Numbers: PRO_010
• First Posted: September 14, 2018
• Last Update Posted: March 10, 2020
• Last Verified: March 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Allotex, Inc.:

Intrastromal; Corneal Inlay

Additional relevant MeSH terms:

Presbyopia; Refractive Errors; Eye Diseases